Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market

Race Oncology has announced its Investigational New Drug application (IND) for Bisantrene Phase 2/3 clinical trial is on hold with the Food and Drug Administration pending outstanding questions.

Bisantrene is a cancer chemotherapy drug which has shown significant activity in several cancers most notably in acute myeloid Leukaemia.

It attacks multiplying cancerous cells and has also been known to have immunologic and genomic effects.

In animal test subjects Bisantrene was found to activate immune cells and then attack and destroy tumour cells. It binds to DNA at a site that displaces telomerase binding proteins which force the tumor cells to lose their immortality and die.

Questions from FDA covered a range of topics including safety, pharmacology, manufacturing, and the trial process.

The second phase of the trial cannot start until the outstanding questions are resolved.

“As we have previously stated, the trial cannot start until we have funding from a licensing partner, so the clinical hold has no immediate impact on the timing of the trial,” Race CEO Peter Molloy stated.

Because of the size and information of the document, there were discussions with the FDA to extend the normal 30-day review period.

Professor Borje Andersson hopes the questions will be answered as the drug will benefit a lot of people.

“This is a drug that has a clear role in AML and I sincerely hope we will see it available for use in treating this disease, in both adults and children,” he said.

Please find the announcement here

RAC by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.